Session Abstract – PMWC 2020 Silicon Valley


The PMWC 2020 Immunotherapy Showcase will provide a 15-minute time slot for selected immunotherapy companies to present their latest technologies and advancements to an audience of leading investors, potential clients, and partners. We will hear from companies building new cell-based immunotherapies, work in the growing area of cancer vaccines, that help understand the relevance of the tumor microenvironment, accelerate the patient selection process, or otherwise work towards overcoming to challenges related to therapeutic discovery.


Confirmed Presenting Companies:

 Speaker Profile

M.D., CEO, Poseida Therapeutics, Inc.

Biography
Dr. Ostertag directed Poseida’s spin out from Transposagen in February 2015 and has served as our chief executive officer and as a member of our board of directors since May 2015. From October 2003 to July 2015, Dr. Ostertag founded and served as the chief executive officer and president of Transposagen Biopharmaceuticals, Inc., a biotechnology company that commercializes early gene editing technology in the research reagent space. Dr. Ostertag previously co-founded and served as chief executive officer and president of Vindico NanoBioTechnology, Inc., a biotechnology company engaged in the discovery, development, and commercialization of human therapeutics that are based on a nanometer-scale particulate technology. Dr. Ostertag also co-founded and served as executive vice president of PhenoTech, Inc., a biotechnology company engaged in the discovery, development, and commercialization of reagents for diagnostic use in blood banks.

Talk
​A Novel Approach To CAR-T Therapy​
CART Therapeutics comprised of a high percentage of stem cell memory T cells exhibit unique properties that could potentially solve most of the limitations of early-generation CART products, including significant toxicities, historically poor efficacy against solid tumors, and high costs.


Immunotherapy Showcase: Poseida Therapeutics, Inc.
Poseida is a clinical-stage biopharmaceutical company leveraging our proprietary next-generation, non-viral gene engineering technologies to create life-saving cell therapeutics for patients with high unmet medical need.

 Speaker Profile

Ph.D., Chief Scientific Officer, Xcell Biosciences

Biography
Dr. Lim is a co-founder of Xcellbio and is currently leading the company’s effort in the development of an advanced primary cell culture and analytics platform. Focused on technologies that enable therapeutic drug development, Dr. Lim is the inventor of the AVATAR cell control system. This IP protected system allows researchers to study primary cells under a diverse range of microenvironments found in the human body. Applications that utilize discrete pressure and oxygen settings were developed by Dr. Lim’s group to expand rare cell types (circulating tumor cells, cancer stem cells), enhance iPSC differentiation into neurons, and predict CAR-T efficacy utilizing autologous model systems. Dr. Lim received his B.Sc. In Cell Biology from McGill University, and his Ph.D. in Biophysics from The Scripps Research Institute. He conducted his post-doctoral studies at Harvard Medical School and launched Xcellbio while working as a researcher at the Lawrence Berkeley National Laboratory.


 Speaker Profile

Ph.D., CEO, Minerva Biotechnologies

Biography
Dr. Bamdad and the Minerva Biotechnologies team are developing CAR T cell therapies for solid tumor cancers. A first-in-human trial is expected to begin in Q1 2019 with colleagues at the Fred Hutchinson Cancer Research Center for metastatic breast cancers that express a MUC1 cleavage product called MUC1* (pronounced muk 1 star). Minerva’s novel cancer immunotherapy targets emerged from focusing on the basic biology of the intersecting space between cancers and naïve stem cells. Dr. Bamdad holds a B.S. in Physics from Northeastern University and a Ph.D. in Biophysics from Harvard University, where she invented an electronic DNA chip that sold to Motorola for $300M in 2000, now marketed by GenMark. Dr. Bamdad served on the Board of Directors of Pharmacyclics during their turn-around from near bankruptcy to $1B deal with J&J for 50% of the drug that would become Imbruvica, followed a few years later by $21B Abbvie acquisition.


Immunotherapy Showcase: Minerva Biotechnologies
Minerva Biotechnologies is a private company developing cancer immunotherapies that disable cancer-specific and patient specific forms of MUC1*.

A 1st-in-Human CAR-T for Solid Tumors That Targets A Cleaved MUC1